Workflow
凝血酶抑制剂
icon
Search documents
趋势研判!2025年中国凝血酶抑制剂行业发展现状及发展趋势研判:市场集中度较高,跨国药企仍主导创新,将向更安全、更精准、更可及的方向发展[图]
Chan Ye Xin Xi Wang· 2025-05-11 00:08
Core Viewpoint - The direct thrombin inhibitors (DTIs) market is poised for growth driven by innovation in drug development, expansion of indications, breakthroughs in biotechnology, and reshaping of market dynamics towards safer, more precise, and accessible treatments [1][25]. Group 1: Industry Definition and Classification - Direct thrombin inhibitors are small molecules that directly inhibit thrombin activity without the need for auxiliary factors, capable of inhibiting both free and clot-bound thrombin [2]. - They are categorized into bivalent and non-bivalent inhibitors based on their mechanism of action [2]. Group 2: Current Industry Status - Thrombotic diseases are a leading cause of death in China, with over 300,000 deaths annually from myocardial infarction and stroke, accounting for 40% of total deaths [4]. - The market has several approved products, including Dabigatran etexilate, Lepirudin, Bivalirudin, Desirudin, and others, with ongoing clinical trials for new drugs [4][6]. - As of mid-2024, the number of companies selling Dabigatran etexilate capsules is 7, with sales of 340.83 million yuan; 15 companies sell Argatroban injection with sales of 140.57 million yuan; and 5 companies sell Bivalirudin injection with sales of 64.67 million yuan [6][8]. Group 3: Market Sales Data - In 2023, Dabigatran etexilate capsules generated sales of 706.14 million yuan, accounting for 53.58% of the DTI market; Argatroban injection sales were 482.25 million yuan (36.59%); and Bivalirudin injection sales were 129.63 million yuan (9.84%) [8]. - In the first half of 2024, Dabigatran etexilate sales reached 340.83 million yuan (62.41%); Argatroban sales were 140.57 million yuan (25.74%); and Bivalirudin sales were 64.67 million yuan (11.84%) [8]. Group 4: Competitive Landscape - The DTI market in China is characterized by a high concentration of multinational pharmaceutical companies, with significant competition from generic and biotech firms [12][15]. - Major players include Boehringer Ingelheim, Chengdu Baitai Pharmaceutical, Tianjin Institute of Pharmaceutical Research, and others, with Boehringer Ingelheim leading with a market share of 21.43% [15][12]. Group 5: Future Development Trends - The DTI industry is expected to focus on innovative drug development, expanding indications, and technological breakthroughs, driven by policy, technology, and patient needs [25]. - The market will likely see increased competition among multinational companies, generics, and biosimilars, aiming for safer and more effective treatments [25].